Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia
US5597800A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 21, 1994 |
| Grant date | Jan 28, 1997 |
| Priority date | — |
| Expiry date | Nov 21, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen alone, in a dosage of about 10-1000 caseinolytic units/kg, can be used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like. Lys-plasminogen can also lessen cerebral edema which results from cerebral ischemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.